BrightGene Bio Medical Technology C
BrightGene Bio-Medical Technology Co., Ltd., together with its subsidiaries, engages in the research, development, production, and sale of pharmaceutical products in China and internationally. The company develops BGM0504 injection, which is in Phase III clinical trial for treatment of type 2 diabetes and weight loss; and BGM1812, a long-acting amylin analog in preclinical development. It also pr… Read more
BrightGene Bio Medical Technology C (688166) - Cash Flow Conversion Efficiency
Latest cash flow conversion efficiency as of June 2023: 0.011x
Based on the latest financial reports, BrightGene Bio Medical Technology C (688166) has a cash flow conversion efficiency ratio of 0.011x as of June 2023.
Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (CN¥26.70 Million) by net assets (CN¥2.35 Billion). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
BrightGene Bio Medical Technology C - Cash Flow Conversion Efficiency Trend (2016–2024)
This chart illustrates how BrightGene Bio Medical Technology C's cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore and compare other companies by cash flow conversion efficiency.
BrightGene Bio Medical Technology C Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of BrightGene Bio Medical Technology C ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Tongyu Heavy Industry
SHE:300185
|
0.004x |
|
EUROCOMM.PR. CERT.10EO 10
F:N4SA
|
N/A |
|
APERAM S.A. NY SHS/1 O.N.
F:7AAN
|
N/A |
|
ELVALHALCOR NA EO 039
F:HC6A
|
N/A |
|
Gentera S.A.B. de C.V
OTCGREY:CMPRF
|
0.037x |
|
Upwork Inc
NASDAQ:UPWK
|
0.101x |
|
The Ramco Cements Limited
NSE:RAMCOCEM
|
0.085x |
|
Griffin-American Healthcare REIT III Inc
PINK:GRAH
|
0.022x |
Annual Cash Flow Conversion Efficiency for BrightGene Bio Medical Technology C (2016–2024)
The table below shows the annual cash flow conversion efficiency of BrightGene Bio Medical Technology C from 2016 to 2024.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | CN¥2.44 Billion | CN¥245.56 Million | 0.101x | +25.06% |
| 2023-12-31 | CN¥2.42 Billion | CN¥194.77 Million | 0.081x | -41.98% |
| 2022-12-31 | CN¥2.24 Billion | CN¥311.26 Million | 0.139x | +37.34% |
| 2021-12-31 | CN¥1.74 Billion | CN¥176.08 Million | 0.101x | -6.82% |
| 2020-12-31 | CN¥1.43 Billion | CN¥155.43 Million | 0.108x | +132.28% |
| 2019-12-31 | CN¥1.31 Billion | CN¥61.33 Million | 0.047x | -43.58% |
| 2018-12-31 | CN¥772.85 Million | CN¥63.99 Million | 0.083x | +3.25% |
| 2017-12-31 | CN¥446.02 Million | CN¥35.77 Million | 0.080x | -40.63% |
| 2016-12-31 | CN¥220.15 Million | CN¥29.73 Million | 0.135x | -- |